Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics
A Bidirectional Cohort Study of Single-Cell Sequencing and Single-Cell Spatial Transcriptomics in Chronic COPD
1 other identifier
observational
150
1 country
1
Brief Summary
This study is an ambispective cohort study, the sample from patients were from both previously stored and freshly collected . The objective of this study is to investigate the molecular pathological changes underlying the development of chronic obstructive pulmonary disease (COPD). We will use single cell sequencing technology to analyze lung tissue samples from patients who underwent lung resection, with lung tissue from patients without COPD serving as controls. This research aims to provide insights into the pathogenesis of COPD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 27, 2025
CompletedStudy Start
First participant enrolled
September 30, 2025
CompletedFirst Posted
Study publicly available on registry
October 6, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
October 6, 2025
September 1, 2025
1.3 years
September 27, 2025
September 27, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Transcriptomic profile analysis of lung tissues
until end of surgery
Study Arms (1)
COPD group
Eligibility Criteria
150
You may qualify if:
- Receiving lung resection surgery at the hospital for any reason;
- Diagnosed with COPD according to the 2024 GOLD guidelines;
- Tissue samples that meet collection requirements and are either agreed to be collected or already preserved;
You may not qualify if:
- Improper preservation of pathological specimens, refusal to consent to sample collection, or incomplete clinical information;
- Combined with other factors causing obstructive airflow limitation;
- Diagnosed with asthma according to the GINA 2023 guidelines and with a history of asthma exacerbations within the past year;
- Combined with Advanced lung cancer;
- Receiving systemic immunosuppressive medications such as anti-rejection drugs;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200444, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
September 27, 2025
First Posted
October 6, 2025
Study Start
September 30, 2025
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2027
Last Updated
October 6, 2025
Record last verified: 2025-09